Main Pipeline

For Your Healthy Life, NovMetaPharma

Anti-obesity Medication (NovOB)

Pipeline
NovOB
Program Target
Obesity
Patient Numbers
1.9 Billion
Development Stage
Phase II
NovMetaPharma develops NovOB, an anti-obesity medication of first-in-class new substance.
Efficacy comparison with major anti-obesity medications

NovOB’s excellent weight loss efficacy and long-term safety have been proven through several clinical and non-clinical trials.

Existing commercial anti-obesity medications have side effects and risks and long-term use is almost impossible as most of them are psychotropic. Also, in the case of the product that takes up the highest market share among anti-obesity medication currently available on the market, the inconvenience of self-injection is pointed out as a major disadvantage.

On the other hand, NovOB is guaranteed to be safe as it is a peptide substance existing in the body and this has been proven through several clinical and non-clinical trials. NovOB reduces weight with just one oral administration a day. As a once-a-day oral medication, NovOB is very convenient to take and patient convenience has been greatly improved by dramatically shortening the dosing interval.

01

Weight loss effect

Significant weight loss effect has been confirmed through the US FDA clinical phase 2 (including a and b).

02

Safety

Safety such as chronic toxicity and reproductive toxicity has been verified through several G140 global clinical and non-clinical trials.

03

Administration convenience

Oral (not injection)

NovOB Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022

Inquiring alternative with NovDB2 clinical phase 2c

License Out (E)

US clinical phase 3

02

Patent Application and Registration Status
Patents IP Protection
Substance patent (US)
Application
2019
Registration
2020
Patent expiration (expected) year
2039
Obesity basic patent (US)
Application
2004
Registration
2006
Patent expiration (expected) year
2024
Obesity basic patent (DE)
Application
2004
Registration
2006
Patent expiration (expected) year
2024
Obesity basic patent (UK)
Application
2004
Registration
2006
Patent expiration (expected) year
2024
Obesity dosage patent (KR)
Application
2018
Patent expiration (expected) year
(2038)